Literature DB >> 18505903

Incidence of hyperthyroidism in Stockholm, Sweden, 2003-2005.

Mirna Abraham-Nordling1, Ove Törring, Mikael Lantz, Bengt Hallengren, Hans Ohrling, Göran Lundell, Jan Calissendorff, Gun Jörneskog, Göran Wallin.   

Abstract

OBJECTIVES: To investigate the incidence of hyperthyroidism in Stockholm County, in those patients who were diagnosed with hyperthyroidism for the first time during the years 2003-2005.
DESIGN: All new cases of hyperthyroidism > or = 18 years of age were prospectively registered to calculate the total incidence of hyperthyroidism, as well as the incidence of the subgroups: Graves' disease (GD), toxic multinodular goitre and solitary toxic adenoma (STA). Eight specialized units/hospitals in Stockholm County participated in the registration. The participating physicians were all specialists in medical endocrinology, oncology, nuclear medicine or surgery.
RESULTS: During a 3-year period, 1431 new patients of hyperthyroidism were diagnosed in a well-defined adult population (> 18 years of age) of in average 1,457,036 inhabitants. This corresponds to a mean annual incidence of hyperthyroidism of 32.7/100,000. The incidence of GD was 24.5/100,000 per year, toxic nodular goitre was 3.3/100,000 per year and STA was 4.9/100,000 per year.
CONCLUSIONS: The total incidence of hyperthyroidism in Stockholm County was found to be 32.7/100,000 per year, of which 75% had GD. There were a higher percentage of smokers among the patients with hyperthyroidism compared with the overall population in Stockholm, but no difference in the frequency of smoking between patients with GD and toxic nodular goitre.

Entities:  

Mesh:

Year:  2008        PMID: 18505903     DOI: 10.1530/EJE-07-0877

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  9 in total

Review 1.  The incidence and prevalence of thyroid autoimmunity.

Authors:  Donald S A McLeod; David S Cooper
Journal:  Endocrine       Date:  2012-05-29       Impact factor: 3.633

2.  Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008.

Authors:  Ana B Emiliano; Laura Governale; Mary Parks; David S Cooper
Journal:  J Clin Endocrinol Metab       Date:  2010-03-24       Impact factor: 5.958

3.  Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers.

Authors:  Annarosa Floreani; Chiara Mangini; Anna Reig; Irene Franceschet; Nora Cazzagon; Lisa Perini; Llorenç Caballería; Silvia Cocchio; Vincenzo Baldo; Albert Parés
Journal:  Am J Gastroenterol       Date:  2016-10-25       Impact factor: 10.864

Review 4.  Thyroid dysfunction in the elderly.

Authors:  Kristien Boelaert
Journal:  Nat Rev Endocrinol       Date:  2013-02-26       Impact factor: 43.330

5.  Cancer risk in patients hospitalised for Graves' disease: a population-based cohort study in Sweden.

Authors:  X Shu; J Ji; X Li; J Sundquist; K Sundquist; K Hemminki
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

Review 6.  Liver failure due to antithyroid drugs: report of a case and literature review.

Authors:  Sarantis Livadas; Xenofon Xyrafis; Frangiskos Economou; Georgios Boutzios; Maria Christou; Aristea Zerva; Athanasios Karachalios; Helen Palioura; Sotiria Palimeri; Evanthia Diamanti-Kandarakis
Journal:  Endocrine       Date:  2010-05-18       Impact factor: 3.925

7.  Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.

Authors:  Cecilie Aass; Ingrid Norheim; Erik Fink Eriksen; Ellen Charlotte Børnick; Per Medbøe Thorsby; Milaim Pepaj
Journal:  PLoS One       Date:  2017-04-18       Impact factor: 3.240

Review 8.  Pediatric Graves' disease: management in the post-propylthiouracil Era.

Authors:  Scott A Rivkees
Journal:  Int J Pediatr Endocrinol       Date:  2014-06-16

9.  Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.

Authors:  David W Vaughn; Harry Seifert; Anne Hepburn; Walthere Dewe; Ping Li; Mamadou Drame; Catherine Cohet; Bruce L Innis; Louis F Fries
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.